Opus Genetics, Inc.
IRDDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
IRD Earnings Report
EPS Est: $-0.15 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How IRD's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AAV8.hLCA5 | Phase 2 | LCA5 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Opus Genetics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Opus Genetics, Inc.'s (IRD) pipeline across Phase 2. Its lead program is AAV8.hLCA5 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Opus Genetics, Inc.'s next FDA catalyst?→
Opus Genetics, Inc.'s (IRD) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IRD biotech catalysts?→
Add IRD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Opus Genetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.